Radiopharmaceutical Tektrotyd continues to receive interest and recognition

Published on November 8, 2012 at 3:51 AM · No Comments

Uranium targets are irradiated for 140 hours to reach the desired molybdenum-99 activity. Once the irradiation cycle is completed, the targets are shipped to the Netherlands for special multi-stage processing applied to produce molybdenum-99. The latter isotope decays to technetium 99m, which is used to label active substance of the 99mTc-Tektrotyd radiopharmaceutical" - explains Janusz Jaroszewicz, NCBJ Coordinator for Irradiations - „The technology of producing technetium-99m is an excellent example of practical application of research reactors in nuclear medicine to save hundreds of thousands of human lives".

Effectiveness of the 99mTc-Tektrotyd kit in unquestionable as confirmed by many scientific reports. The reports have been verified by the market: the radiopharmaceutical has been positively evaluated by clinicians and attracts plenty of interest home and abroad.

„The just concluded in Milan EANM Congress is for us another confirmation that the accepted strategy to manufacture Tektrotydis effective"- points out Dr. Dariusz Socha, NCBJ POLATOM Director - „Our product is among just three in the world so-far registered medicines based on peptide analogues as carriers of radioisotope labels".

Awards granted to NCBJ POLATOM Radioisotope Centre for development and manufacture of Tektrotyd include Minister of Science and Education Honourable Mention (2006), 2008 Innovation of the Year Contest Prize Winner, 2008 Polish Product of the Future Contest Honourable Mention, Gold Medal at the INNOVA 58th International Exhibition of Innovation, Research and New Technologies (Brussels, 2009).

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment